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Oxidative stressNewly designed triazolothiadiazines incorporating with structural motifs of nonsteroidal analgesic anti-
inflammatory drugs were synthesized and screened for their bioactivity against epithelial cancer cells.
Compounds with bioactivities less then 5 lM (IC50) were further analyzed and showed to induce apop-
totic cell death and SubG1 cell cycle arrest in liver cancer cells. Among this group, two compounds (1g and
1h) were then studied to identify the mechanism of action. These molecules triggered oxidative stress
induced apoptosis through ASK-1 protein activation and Akt protein inhibition as demonstrated by
downstream targets such as GSK3b, b-catenin and cyclin D1. QSAR and molecular docking models provide
insight into the mechanism of inhibition and indicate the optimal direction of future synthetic efforts.
Furthermore, molecular docking results were confirmed with in vitro COX bioactivity studies. This study
demonstrates that the novel triazolothiadiazine derivatives are promising drug candidates for epithelial
cancers, especially liver cancer.
 2016 Published by Elsevier Ltd.1. Introduction that these agents exhibit anticancer activity through COX-depen-Cancer related deaths are growing at a faster rate than expected
despite the improvements in early detection and advanced treat-
ment strategies, including radical surgery along with chemother-
apy and radiotherapy. According to World Health Organization
(WHO) data, cancer is recently ranked primary cause of death
replacing cardiovascular diseases throughout the world.1 Che-
motherapy is employed as a crucial part of the multimodal treat-
ment of cancer when surgery is not suitable. However, poor
cytotoxic efficacy, severe dose-limiting toxicity and resistance
resourcing from various factors restrict the chemotherapeutic
responses of available drugs. Therefore, discovery of efficient cyto-
toxic agents with improved selectivity against cancer is still an
attractive field.2
As an innovative approach in drug design, some common non-
steroidal anti-inflammatory drugs (NSAIDs) (aspirin, ibuprofen,
naproxen, meloxicam, celecoxib, etc.) have been repurposed for
anticancer drug research.3–7 There are noteworthy studies claimdent or independent pathways.3,4,7–11 Experimental studies and
clinical observations on individuals taking regular and long-term
NSAIDs showed a reduced risk of cancer incidence.2,3,12–14 Addi-
tionally, conventional NSAIDs and selective COX-2 inhibitors have
been reported to possess cancer chemopreventive effects or lower
carcinogenesis risk.2–4,8,13,14 However, insufficient risk-benefit con-
sideration, failure of dose-treatment time determination and
unclear safety profiles limit the use of NSAIDs in cancer
chemoprevention.13
The synthesis and analgesic/anti-inflammatory evaluation of
various condensed heterocyclic systems derived from 1,2,4-tria-
zole-5-thiones have been discussed within our extensive research
program for fifteen years.15–21 Lately, we have focused on tria-
zolothiadiazine and triazolothiadiazole scaffolds22–24, known to
have significant biological activities.25 In recent years, these scaf-
folds have attracted attention because of their cytotoxic
effects.26–33 This considerable background has directed us to inves-
tigate the anticancer effect of our compounds bearing a triazoloth-
iadiazine core.34 The encouraging results we obtained, and the
impressive history of NSAIDs in the cancer research field, have
inspired us to design new hybrid compounds by combining a
1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine ring with the commercially
available NSAIDs, ibuprofen, naproxen and flurbiprofen, that are
expected to have enhanced anticancer activity.
P. S. Aytaç et al. / Bioorg. Med. Chem. 24 (2016) 858–872 859In this study the bioactivities of novel triazolothiadiazines were
tested initially on epithelial cancer cells, then the mechanism of
action was examined with liver cancer cells. Hepatocellular carci-
noma (HCC) is among the most-deadly cancers according to the
World Cancer Report 2014.1 Percutaneous ablation and transplan-
tation surgery are treatment options for early tumors, however,
advanced tumors usually acquire palliative therapy.35–37 Limited
treatment options and resistance to conventional chemotherapy
and radiotherapy35 made vital novel targeted therapeutic agent
development for treatment of HCC. Herein, we demonstrate the
putative in vitro anticancer properties of our newly designed tria-
zolothiadiazines as well as the death mechanism they trigger in
liver cancer cells.2. Results and discussion
2.1. Chemistry
4-Amino-1,2,4-triazole-5-thiones (1–3) and 1,2,4-triazolo[3,4-
b]-1,3,4-thiadiazines (1a–3j) were acquired according to the path-
way that was reported in our previous articles22,23 as illustrated in
Scheme 1. Briefly, aminomercaptotriazoles (1–3) derived from
NSAIDs were obtained by fusing the traditionally available drugs
(ibuprofen, naproxen or flurbiprofen) carrying an aliphatic car-
boxylic acid group, with thiocarbohydrazide at its melting point
(170 C). The title compounds, triazolothiadiazines, were
achieved from a one-pot synthesis of compounds 1–3 and corre-
sponding 2-bromo/2-chloro-substituted acetophenones in anhy-
drous ethanol under reflux. As a time-saving option, they were
also obtained by microwave-promoted synthesis with less ballast
product.
All compounds were characterized by their melting points, ele-
mentary analysis, infrared, 1H NMR and mass spectra. The spectral
data matched the proposed structures. Although compounds 1–3
have been reported by Metwally et al.,38 their reported melting
points did not match our data. Therefore, we performed all the
characterization assays once again for compounds 1–3. In the IR
spectra of compounds 1–3, vibrations appeared at 1167–
1153 cm1, which corresponded to C@S stretching bands, and
absence of stretching bands at about 2700–2500 cm1, attributable
to an SAH bond, which revealed that compounds 1–3 are present
in thione form in the solid state. The disappearance of the bands
subjected to NAH and C@S in the IR spectra of the resulting com-
pounds have confirmed a thiadiazine ring closure.
In the 1H NMR spectra, –SCH2 protons were split into two dou-
blets, while we expected a singlet peak. So we recorded a NOESYR CH
CH3
COOH + H2NNH C NHNH2
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Scheme 1. Synthetic pathways of the compounds 1–3 and 1a–3j. Reagents and
conditions: (i): heat (170 C), (ii): abs. ethanol, reflux or ethanol/microwave
energy.spectrum of compound 1a to clarify the doublet signals of the –
SCH2 protons, and saw that geminal protons caused two indepen-
dent doublet splittings according to an AB spin system.
The mass fragmentation of the compounds was studied under
electron spray ionization (ESI). The peaks of quasimolecular ions
[M++H] or [M++Na], which appeared at different intensities, con-
firmed the molecular weights of the examined compounds.
Analytically pure samples were subjected to cytotoxic
evaluation.2.2. Pharmacology
2.2.1. Cytotoxic evaluation of synthesized compounds with an
NCI-SRB assay39
We first assessed all synthetic derivatives (aminomercaptotria-
zoles (1–3), 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines (1a–3j)) and
commercially available NSAIDs (ibuprofen, naproxen and flur-
biprofen) for their cytotoxic activities against liver (Huh7), breast
(MCF7) and colon (HCT116) human cancer cell lines in vitro.
Campthotecin (CPT, a DNA topoisomerase inhibitor) was chosen
as a positive control and DMSO as a negative vehicle control for
the cytotoxic effect. The cells were treated with the compounds
in increasing concentrations (2.5–40 lM) and their IC50 values
were calculated. All triazolothiadiazine derivatives (1a–3j)
inhibited cell proliferation with IC50 values in the range of
1.1–18.8 lM, as shown in Table 1, neither NSAIDs nor starting
compounds (1–3) showed significant cytotoxic effects in the pre-
liminary screening. Therefore, we could propose an initial struc-
ture-activity relationship conclusion that fusing a 1,2,4-triazole
ring with a thiadiazine is essential for cytotoxic activity. Numerous
compounds bearing ibuprofen (1a–j) or flurbiprofen (3a–j) resi-
dues at the third position of the triazolothiadiazine core demon-
strated significant cytotoxicity with preferential activity against
the Huh7 cell line when compared to the naproxen (2a–j) counter-
part. Nonetheless, varying substituents on the phenyl ring at the
sixth position of the triazolothiadiazine core did not dramatically
change the cytotoxic strength of the compounds. Even though it
is hard to draw an overall SAR conclusion related to these results,
some generalizations can be established (further detailed QSAR
analysis given below):
Ibuprofen compounds carrying an electron-donating group
(4-methyl (1g), 4-methoxy (1h) and 4-trifluoromethoxy (1j)) and
flurbiprofen compounds carrying an electron withdrawing group
(4-fluoro (3b), 4-chloro (3c), 2,4-dichloro (3d), 4-bromo (3e)
and 4-nitro (3f)) attached to the phenyl ring at the sixth position
of the triazolothiadiazine showed lower IC50 than 5.5 lM on the
Huh7 cell line. Compound 1e, which has an electron-withdrawing
atom (4-bromo), and 3h, which bears an electron-donating group
(4-methoxy), both attached to the phenyl ring, also represented
very good cytotoxicity, as two exceptions to the classification
above. In the ibuprofen series (1a–j), 1j (IC50 of 3.6 lM for
Huh7, 1.1 lM for MCF7, 3.0 lM for HCT116) was found to be
the most active compound, followed by 1e (IC50 of 4.9 lM for
Huh7, 9.4 lM for MCF7, 7.1 lM for HCT116), 1g (IC50 of 5.0 lM
for Huh7, 6.3 lM for MCF7, 4.0 lM for HCT116) and 1h (IC50 of
5.3 lM for Huh7, 5.2 lM for MCF7, 4.2 lM for HCT116). In the
flurbiprofen series (3a–j), 3d (IC50 of 3.7 lM for Huh7, 7.6 lM
for MCF7, 6.9 lM for HCT116) showed the best cytotoxicity, fol-
lowed by 3c (IC50 of 3.9 lM for Huh7, 8.7 lM for MCF7, 7.8 lM
for HCT116), 3f (IC50 of 4.3 lM for Huh7, 7.8 lM for MCF7,
7.1 lM for HCT116), 3h (IC50 of 4.3 lM for Huh7, 2.6 lM for
MCF7, 4.4 lM for HCT116), 3b (IC50 of 4.9 lM for Huh7, 8.1 lM
for MCF7, 10.5 lM for HCT116) and 3e (IC50 of 5.0 lM for
Huh7, 7.4 lM for MCF7, 7.1 lM for HCT116) against the Huh7
cell line (Table 1).
Table 1
IC50 (lM) values of the compounds as a result of the SRB assay
Compds Huh7 MCF7 HCT116 Compds Huh7 MCF7 HCT116
Ibu 37.2a ± 16 NI NI 2c 5.6 ± 1.4 10.1 ± 1.6 8.8 ± 1.2
Nap NIb NI NI 2d 10.7 ± 2.5 14.6 ± 2.1 14.0 ± 0.3
Flu NI NI NI 2e 9.3 ± 6.3 11.5 ± 0.8 11.7 ± 2.5
1 67.9 ± 5.7 16.1 ± 6.6 27.4 ± 6.6 2f 14.7 ± 4.5 18.8 ± 2.4 15.1 ± 1.9
2 40.8 ± 1.2 22.3 ± 8.0 20.2 ± 10 2g 8.2 ± 1.9 11.0 ± 1.3 10.2 ± 0.9
3 NI NI NI 2h 8.5 ± 0.1 6.6 ± 0.1 6.5 ± 3.5
1a 6.1 ± 1.2 9.7 ± 3.0 7.6 ± 0.2 2i 14.8 ± 1.5 6.9 ± 0.1 10.8 ± 3.1
1b 7.8 ± 2.2 8.9 ± 0.8 12.4 ± 0.5 2j 16.0 ± 7.0 8.8 ± 0.8 11.7 ± 3.0
1c 5.7 ± 2.5 8.8 ± 1.1 6.7 ± 1.2 3a 6.7 ± 2.3 7.4 ± 1.3 9.7 ± 1.6
1d 7.5 ± 4.0 11.8 ± 3.0 11.1 ± 4.7 3b 4.9 ± 2.8 8.1 ± 3.5 10.5 ± 2.2
1e 4.9 ± 1.4 9.4 ± 0.6 7.1 ± 0.2 3c 3.9 ± 1.0 8.7 ± 0.5 7.8 ± 0.3
1f NI NI NI 3d 3.7 ± 0.3 7.6 ± 0.5 6.9 ± 0.7
1g 5.0 ± 0.2 6.3 ± 0.7 4.0 ± 0.6 3e 5.0 ± 2.5 7.4 ± 1.7 7.1 ± 4.4
1h 5.3 ± 4.0 5.2 ± 1.6 4.2 ± 4.0 3f 4.3 ± 3.0 7.8 ± 2.7 7.1 ± 0.8
1i 8.4 ± 1.8 4.2 ± 0.9 6.5 ± 0.2 3g 7.2 ± 0.3 5.0 ± 1.1 4.8 ± 0.2
1j 3.6 ± 1.8 1.1 ± 0.8 3.0 ± 2.9 3h 4.3 ± 1.5 2.6 ± 1.7 4.4 ± 0.9
2a 5.7 ± 2.9 11.7 ± 3.0 8.9 ± 0.8 3i 9.4 ± 1.6 4.3 ± 4.3 6.1 ± 0.02
2b 7.0 ± 3.8 15.8 ± 3.8 13.1 ± 0.5 3j 8.4 ± 0.9 4.8 ± 0.6 5.4 ± 1.1
a Represents IC50 values.
b NI stands for ‘No Inhibition’. ‘±’ represents standard deviations, R2 P 0.8. IC50 for positive control (CPT) was 60.1 lM.
860 P. S. Aytaç et al. / Bioorg. Med. Chem. 24 (2016) 858–872The compounds with significant cytotoxic activities (1e, 1g, 1h,
1j, 3b, 3c, 3d, 3e, 3f, 3h), the aminomercaptotriazoles (1–3) and the
NSAIDs were selected for further evaluation. The bioactivities of
these compounds were analyzed on a panel of HCC cell lines:
HepG2, Hep-3B, Mahlavu, FOCUS and Snu475. Similar to initial
screening results, the NSAIDs and compounds 1–3 displayed low
or no cytotoxic activity. All selected condensed derivatives dis-
played significant cytotoxic activities (Table 2).
2.2.2. Real time cell growth analysis with selected compounds
For dynamic and quantitative measurements of the cytotoxic
effects of the compounds 1e, 1g, 1h, 1j, 3b, 3c, 3d, 3e, 3f and 3h,
a label-free, real-time cell electronic sensing (RT-CES) assay was
performed with Huh7 cells. Cells were treated with the compounds
according to their IC100, IC50 and IC25 concentrations and cell impe-
dance was monitored during 72 h. The graphs represent time-
dependent effects of the seleceted compounds on cell growth
(Fig. 1). The results were normalized to DMSO-treated control cells.
In general, apoptosis is a cellular process usually triggered after
the fourth hours of anticancer drug treatment and may take up to
24 h in cancer cell lines. The time-dependent growth inhibition
graphs demonstrated cytotoxicities in parallel to IC100, IC50 and
IC25 values obtained from initial cytotoxicity analysis (Tables 1Table 2
IC50 (lM) values of the compounds as a result of the SRB assay on the liver carcinoma ce
Compds Huh7 HepG2 Hep-3
Ibu 37.2a ± 16 NI NI
Nap NIb NI NI
Flu NI NI NI
1 23.0 ± 2.3 NI 13.1 ± 2
2 NI 40.0 ± 0.2 1.9 ± 3
3 43.1 ± 3.7 21.4 ± 3.2 NI
1e 9.4 ± 1.9 6.4 ± 2.3 8.3 ± 0
1g 6.2 ± 0.1 7.3 ± 1.3 5.3 ± 0
1h 3.7 ± 1.3 3.8 ± 0.6 6.5 ± 0
1j 9.5 ± 0.5 9.7 ± 0.9 6.4 ± 0.
3b 6.3 ± 0.7 5.1 ± 3.0 2.6 ± 1
3c 6.4 ± 1.9 6.7 ± 2.2 3.8 ± 0
3d 7.3 ± 0.8 8.6 ± 1.5 4.2 ± 1
3e 8.7 ± 1.9 3.7 ± 0.6 1.5 ± 1
3f 7.1 ± 2.2 4.3 ± 4.1 2.9 ± 2
3h 4.5 ± 1.9 4.2 ± 1.6 3.5 ± 1
CPT 0.1 <1 <1
a Represents IC50 values.
b NI stands for ‘No Inhibition’. ‘±’ represents standard deviations R2 P 0.8.and 2). The course of cell growth inhibition predicts the type of cell
death as apoptosis which was further analyzed below.
2.2.3. Characterization of cell death as apoptosis
Cells were treated with 10 lM of the compounds and compared
to DMSO control. After 48 h, the Hoechst-dye-stained cells’ nuclei
were observed under a fluorescence microscope. As seen in Fig-
ure 2, the cell morphologies of the compound-treated cells were
distinctive from the DMSO-treated cells; condensed bright nuclei
and a ‘horseshoe’ structure indicated apoptotic cells in treated
samples (except 3e and 3f). Furthermore, apoptosis was confirmed
with 1g and 1h by the presence of cleaved-PARP protein below.
2.2.4. Cell cycle analysis of compound-treated cells
To further elucidate the apoptotic cell death, we checked the
effects of the compounds 1e, 1g, 1h, 1j, 3b, 3c, 3d, 3e, 3f and 3h
with cell-cycle analysis in Huh7 cells. Cells were treated with
10 lM of the compounds or DMSO controls for 24-hour and 48-
hour periods and the comparative cell fate was measured.
Analysis of histograms showed that there was an apparent
increase in SubG1 cell population in the presence of 1e, 1g, 1h,
3c and 3h indicating apoptotic cell death (Fig. 3).ll line panel
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<1 <1 <1
Figure 1. Real-time growth of Huh7 cells in the presence of compounds 1e, 1g, 1h, 1j, 3b, 3c, 3d, 3e, 3f and 3h. Results were normalized to DMSO-treated cells. Cell growth
index was acquired every 30 min.
Figure 2. Morphological changes in Huh7 cell nuclei induced by compounds 1e, 1g, 1h, 1j, 3b, 3c, 3d, 3e, 3f and 3h. Cells were stained with Hoechst 33258 dye and observed
under a fluorescence microscope. Control group was DMSO. Images were taken with 40x objectives.
P. S. Aytaç et al. / Bioorg. Med. Chem. 24 (2016) 858–872 861We have selected the compounds carrying ibuprofen residue at
the third position of the thiadiazine ring 1g (3-[1-[4-(2-methyl-
propyl)phenyl]ethyl]-6-(4-methylphenyl)-7H-1,2,4-triazolo[3,4-
b]-1,3,4-thiadiazine) and 1h (3-[1-[4-(2-methylpropyl)phenyl]
ethyl]-6-(4-methoxyphenyl)-7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadi-
azine) for further mechanistic analysis leading to apoptotic cell
death with two different liver cancer cells (Huh7 and Mahlavu).
2.2.5. Compounds 1g and 1h induced oxidative stress in liver
cancer cells
NSAIDs were shown to induce oxidative stress, which may be a
mechanism for the anticancer activity of our compounds.40 There-
fore,we investigated the induction of oxidative stresswith novel tri-azolothiadiazine derivatives 1g and 1h in human liver cancer cell
lines, Huh7 and Mahlavu (MV). Cells were treated with 10 lM of
compounds for 48 h and then analyzed with flow cytometry. Both
1g and 1h treatment resulted in accumulation of reactive oxygen
species (ROS) positive cells when compared to DMSO controls
(Fig. 4A). In this assay, cells grown in selenium deficient serum free
medium were used as positive controls of ROS accumulation.41
Moreover, in order to confirm the induction of oxidative stress,
we analyzed in situ ROS accumulation with dichloro-dihydro fluo-
rescein diacetate (DCFH-DA) under fluorescent microscope. This
assay also verified in situ the accumulation of ROS positive cells
leading to oxidative stress induction in the presence of both com-
pounds 1g and 1h (Fig. 4B).
Figure 3. Cell cycle analysis of Huh7 cells treated with compounds or DMSO controls after (A) 24-hour and (B) 48-hour of incubation.
Figure 4. Oxidative stress induction. (A) Human liver cancer cells (Huh7 and Mahlavu (MV)) were either treated with 10 lM of compounds, or DMSO control or grown in
selenium deficient medium for 48 h. Oxidative stress induction was monitored by flow cytometry. ROS (positive) cells were indicated in red and ROS (negative) cells were
indicated in blue. (B) Cells were stained in situ with DCFH-DA and images were acquired under fluorescent microscope (40). Green fluorescent cells indicate presence of
ROS.
862 P. S. Aytaç et al. / Bioorg. Med. Chem. 24 (2016) 858–8722.2.6. Apoptosis due to 1g and 1h involves phosphorylation of
b-catenin
Previous findings demonstrated that ibuprofen might exhibit its
chemopreventive activity through b-catenin oncogene inhibition.3
Therefore, we investigated the levels of both phosphorylated and
un-phosphorylated forms of b-catenin in liver cancer cells treated
with 1g and 1h. The compounds led to an increase in b-catenin
phosphorylation, which targets this protein for degradation, while
no change was observed in un-phosphorylated b-catenin levels
(Fig. 5A). It was shown that the upstream regulators of b-cateninare Akt and GSK3b proteins.42 Thus, we also checked status of these
proteins in the presence of the compounds. 1g and 1h caused sig-
nificant decrease in phosphorylated active form of Akt (p-Akt) and
phosphorylated inactive form of GSK3b (p-GSK3b) (Fig. 5A). While
Akt pathway is hyperactive in Mahlavu cells due to PTEN deletion,
in Huh7 cells, the pathway is not hyperactive. For this reason,
p-Akt bands were observed only in Mahlavu but not in Huh7 cells
(Fig. 5A). Moreover, it was suggested that b-catenin transcription-
ally activates cyclin D1, which is an important factor of cellular
replication machinery.42 In liver cancer cells treated with
P. S. Aytaç et al. / Bioorg. Med. Chem. 24 (2016) 858–872 863compounds 1g and 1h, levels of cyclin D1 significantly decreased
due to b-catenin phosphorylation, when compared to the DMSO
controls (Fig. 5A).
Since we have shown that compounds 1g and 1h induced
oxidative stress, we also investigated ASK-1 and JNK proteins that
are reported to be involved in this process. Our data showed that
1g and 1h decreased the levels of ASK-1 phosphorylation at
Ser83 or Ser966, which are the residues phosphorylated due to
oxidative stress. Phosphorylation at Ser83 and Ser966 leads to inhi-
bition of this protein. Thus, decrease in these forms of the proteinFigure 5. Mechanistic analysis of 1g and 1h bioactivities in liver cancer cells. Huh7 and
changes in protein levels were investigated using specific antibodies with western blot a
protein levels and phosphorylation. 1g and 1h induced the inhibition of Akt phosphoryla
Then the decrease in p⁄b-catenin and cyclin D1 results in apoptotic cell death inductionindicates the activation of ASK-1 by 1g and 1h in treated liver can-
cer cells (Fig. 5B). Due to the activation of ASK-1, downstream tar-
get SAPK/JNK protein was shown to be phosphorylated in the
presence of 1g and 1h (Fig. 5B). Finally, induction of oxidative
stress by 1g and 1h leads to apoptotic cell death as demonstrated
by the presence of cleaved PARP protein (Fig. 5B) in addition to cell
cycle analysis (Fig. 3).
Together our results demonstrated that compounds 1g and 1h
cause ROS accumulation, which in turn results in the inhibition
of Akt cell survival protein, and the activation of ASK-1 protein.Mahlavu cells were treated with 1g, 1h or DMSO controls for 24 h and 48 h. The
nalysis. ROS activated Akt pathway (A) and ASK1 pathway (B) indicates differential
tion, and activation of ASK1, which results in activation of JNK and GSK3b proteins.
shown by PARP cleavage. b-actin was used for equal protein loading.
Figure 6. The proposed action mechanism of 1g and 1h. Novel compounds resulted in the induction of oxidative stress (ROS), which then caused the activation of ASK-1 and
the inactivation of Akt. ASK-1 in return activates SAPK/JNK. On the other hand, inhibition of Akt resulted in activation of GSK3b (non-phosphorylated form), which induced
phosphorylation of b-catenin and thus its degradation. b-catenin, which is involved in transcriptional activation of cyclin D1, cannot activate the transcription of this protein.
In addition, active GSK3b induces the cyclin D1 degradation. Finally, 1g and 1h induces SubG1/G1 arrest and apoptotic cell death in liver cancer cells.
864 P. S. Aytaç et al. / Bioorg. Med. Chem. 24 (2016) 858–872ASK-1 then activates JNK protein and induction of apoptosis. On
the other hand, inhibition of Akt results in the activation of GSK3b.
Active GSK3b induces phosphorylation of b-catenin therefore its
degradation. Treatment with 1g and 1h significantly altered cyclin
D1 levels by the inhibition of its transcriptional activator b-catenin
and activation of its degradation by GSK3b. Decrease in cyclin D1
protein levels leads to SubG1 arrest and induction of apoptosis in
liver cancer cells treated with 1g and 1h compounds (Fig. 6).
2.3. In silico analysis
2.3.1. QSAR
It is known that SAR discontinuity (where small changes in
chemical structure lead to large changes in activity, also known
as ‘activity cliffs’) presents a challenge to successful QSAR model-
ing.43 At first glance, it would appear that the lack of inhibition
exhibited by 1f represents an activity cliff since all other com-
pounds based on scaffold 1, and 2f and 3f, show good activity.
However, the lack of activity of 1f does not fit the definition of
an activity cliff; it is useful to consider activity cliffs only if one cliff
partner has a potency in the nanomolar range.44 Since none of the
inhibitors in this dataset exhibit such potency, the real difference
in activity between 1f and the other compounds is insufficient
for this to be a barrier to QSAR modeling.A QSAR model was built using QSARINS with the average IC50
values of the compounds against the three cancer cells lines used
as the activity response variable (Table 1). The model was evolved
via Genetic Algorithm in multiple iterations until a maximum of
three descriptors was reached; the predictive performance
achieved at this level of complexity was sufficient so the number
of variables was not increased to prevent over-fitting and produce
a maximally simple model suitable for future use.
The R2 of the best model that passed the maximum number of
external validation tests (4 out of 5) was 0.70 (with an adjusted
R2 of 0.64; unlike R2, the adjusted R2 increases when a new
explanator is included only if the new explanator improves the
R2 more than would be expected by chance45), showing good cor-
relation with experimental IC50 (Fig. 7). Details of the three
descriptors used for this model, the model equation, and the
inter-descriptor correlations are listed in Table 3.
None of the descriptors can be considered highly collinear with
another, meaning that each is contributing substantially to the pre-
diction.50,51 None of the compounds included in the final model
building had errors in prediction larger than a factor of 10
(Fig. 7), suggesting an applicability domain sufficiently broad for
the model to be useful, and that all structural outliers had been
correctly identified and removed. The final QSAR model resulting
from this work therefore appears robust.
Figure 7. Experimental activities versus activities predicted by the model.
Table 3
Details of the best QSAR model selected by Genetic Algorithm
Descript or
details
SpMax8_Bhv Burden modified eigenvalues46,47
VR1_DzZ Randic-like eigenvector-based index from the
Barysz matrix46,48
BIC2 Bond information content (neighborhood
symmetry of 2-order)46,49
Model equation IC50 (lM) = 104.5854 + 29.0229
SpMax8_Bhv + 44.9803 BIC2 + 0.0043
VR1_DzZ
Inter-descriptor correlations (R2) VR1_DzZ—SpMax8_Bhv 0.5047
VR1_DzZ—BIC2 0.1957
SpMax8_Bhv—BIC2 0.0291
P. S. Aytaç et al. / Bioorg. Med. Chem. 24 (2016) 858–872 8652.3.2. Molecular docking
The origins of the lack of inhibitory activity of compound 1f
were investigated by molecular docking. Models of Ibu and Flu
present in crystal structures 1EQG and 1EQH respectively were
re-docked into COX-1 using Autodock, which correctly reproduced
their known binding modes, with RMSDs of 0.9 and 1.2 Å (Supple-
mentary data Figs. S69A and S69B, respectively). Nap was also
docked and, although no crystal structure is available of it in com-
plex with COX-1 or -2, it was predicted to bind in a mode similar to
that of Ibu and Flu, consistent with a shared pharmacophore (Sup-
plementary data Fig. S69C).
Compounds 1f, 1g, 1h, and 1j were docked into COX-1 (PDB
code 1EQG). All but 1f could be accommodated by the binding site
pocket in a pose consistent with the known binding positions of
the Ibu, Flu and Nap anchor fragments. Figure 8B–D show the
1g, 1h, and 1j docking poses; they are positioned such that their
methylpropylphenyl moieties are still encompassed by the
hydrophobic basin formed by Val349, Leu352, Phe518 and Ile523.
In contrast, Autodock calculated that the 1f pose with the lowest
binding free energy is situated completely outside of this deep
pocket, in a shallower depression on the surface of the protein
(Fig. 8A).
This compromised binding mode is reflected in the predicted
binding affinities, which are significantly tighter for 1g, 1h, and1j than for 1f. It is interesting that a relatively minor change in
functional group exhibits such a marked influence on binding;
the nitro group present in 1f is differentiated from all of the other
R0 groups in that it carries a substantial anisotropic charge distribu-
tion. Manual alchemical transformation of the docked poses of 1g,
1h, and 1j into 1f reveals that the negatively charged oxygen atoms
of this nitro group are positioned close to Glu524. Thus, charge
repulsion may be the origin of the suboptimal predicted binding
mode, and lack of activity, exhibited by this compound. To test this
hypothesis, compounds 2f and 3f, which both carry the nitro group
(and yet exhibit good activity), were also docked into COX-1. By
forming additional hydrophobic contacts with the deeper part of
the hydrophobic basin (formed by Phe381, Leu384, Tyr 385 and
Trp387), the larger aromatic moieties of these compounds pull
the molecules’ binding positions further into the pocket, moving
the nitro group away from Glu524 and additionally allowing it to
form hydrogen bonds with the side chain of Arg83 (Fig. 9). These
modeling results are consistent with the primary mode of action
of these compounds being through COX inhibition, which in turn
is consistent with them being derivatives of known COX inhibitors.
2.3.3. Confirmation of molecular docking by COX inhibition
analysis
Considering the docking results that may refer to COX inhibi-
tory activities of compounds 1g and 1h, they were further investi-
gated with COX activity assay in vitro. COX enzyme activity was
analyzed in the presence of Huh7 and Mahlavu liver cancer cells
treated with 1g and 1h, and results revealed that, both 1g and
1h possess COX inhibition. Ibu, Nap and Flu showed COX inhibi-
tion more than 70% whereas the inhibition was 65% in Huh7 and
55% in Mahlavu cells treated with 1h and 54% in Huh7 and 32%
in Mahlavu cells treated with 1g. These results indicated that both
1g and 1h inhibit COX enzyme activity, in addition to their oxida-
tive stress related anticancer activities (Fig. 10, Supplementary
data Fig. S70). The results are found to be in correlation with in sil-
ico molecular docking results of the compounds. Previous studies
showed that decreased phosphorylation of Akt via COX-2 inhibi-
tion caused apoptosis in HCC cells.52,53 Therefore, it could be con-
cluded that the compounds might act on the inhibition of Akt
pathway through COX proteins in addition to ASK-1 and JNK
proteins.
3. Conclusions
In this study we synthesized 30 new triazolothiadiazine deriva-
tives (1a–3j), starting with the traditional NSAIDs (ibuprofen,
naproxen and flurbiprofen) and then examined their antiprolifera-
tive properties and mechanism of action in liver cancer cells. The
majority of derivatives showed moderate to significant cytotoxic-
ity. As a general consideration, our results confirmed that condens-
ing an aminomercaptotriazole ring (1–3) with a thiadiazine
provides better results for cytotoxic activity. The most interesting
series of compounds are those having ibuprofen, [1-[4-(2-methyl-
propyl)phenyl]ethyl] (1a–j), and flurbiprofen, [1-(2-fluoro-4-biphe-
nyl)ethyl] (3a–j), residues at the third position of the ring. Many
of the compounds also showed cytotoxic activity against epithelial
cancer cells (Huh7, MCF7 and HCT116). Among them, compounds
1e, 1g, 1h, 1j, 3b, 3c, 3d, 3e, 3f and 3h, had lower IC50 values which
were further studied in various human liver cancer cells.
According to fluorescent microscopy and flow cytometry analy-
sis, the compounds 1e, 1g, 1h, 3c and 3h were found to induce
apoptosis and SubG1 arrest. Two of the compounds (1g and 1h)
were then selected for the investigation of mechanism of action
at protein levels. It was reported that chemopreventive actions of
NSAIDs, involves induction of ROS along with b-catenin oncogene
Figure 8. Docking results. All side chain residues within 5 Å of all of the docking results are shown as green lines, and the protein backbone is shown as black cartoon
depicting secondary structure. A) 1f (cyan) B) 1g (yellow) C) 1h (magenta) D) 1j (pink).
Figure 9. Docking results. All side chain residues within 5 Å of the docking results
are shown as green lines, and the protein backbone is shown as black cartoon
depicting secondary structure. Hydrogen bonds between their nitro groups and
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Figure 10. Effect of 1g and 1h on COX enzyme activity. Huh7 and Mahlavu (MV)
liver cancer cells were treated with 10 lM of novel compounds or NSAIDs (Ibu, Nap,
Flu) or DMSO controls for 48 h. Then COX enzyme activity was assayed. Novel
compounds 1g and 1h showed significant COX enzyme inhibition in liver cancer
cells compared to DMSO controls.
866 P. S. Aytaç et al. / Bioorg. Med. Chem. 24 (2016) 858–872inactivation.3,41 Hence, we also demonstrated the accumulation of
ROS and the activation of ROS dependent apoptosis signal regulat-
ing kinase-1 (ASK-1) and inhibition of Akt protein in the presence
of 1g and 1h (Figs. 5 and 6). As a result of ASK-1 activation, and Akt
inhibition, a number of downstream proteins including b-catenin
were altered resulting in cyclin D1 inactivation and ultimately
leading to SubG1 arrest and apoptosis (Figs. 5 and 6). In the in silico
docking analysis, we observed possible interactions of 1g and 1h
with COX proteins, which is then, confirmed with COX activity
assay. According to COX activity assay, both compounds showed
COX-inhibiting activities that is comparable to the conventional
NSAIDs (Fig. 10).
The statistically valid QSAR model based on a small number of
theoretical molecular descriptors developed can be used to guidefuture decisions regarding which derivatives to synthesize; this
has been facilitated by the use of freely available descriptor gener-
ation and QSAR modeling software. The chemical applicability
domain and the reliability of the predictions was validated via
multiple statistical tests. A group of 3 descriptors identified suffi-
cient structural features necessary to model assay activity. Molec-
ular docking provided support for the hypothesis that these NSAID-
derived compounds bind one or more of the COX enzymes,
although activity via additional off-target effects cannot be ruled
out. The docking also provided a plausible explanation for the
unexpected lack of activity exhibited by one of the compounds.
On the other hand the docking results decipher the induction of
oxidative stress by these compounds.
The results we obtained in this study proposes novel triazoloth-
iadiazine derived compounds can be good candidates for the treat-
ment of epithelial cancers particularly liver cancer which has
limited therapeutic options.
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4.1. Chemistry
All chemicals were purchased from Sigma–Aldrich Chemical Co.
(Steinheim, Germany). Melting points were detected with a
Thomas Hoover capillary melting point apparatus (Philadelphia,
PA, USA) and were uncorrected. IR spectra were recorded on a Per-
kin Elmer 1720X FT-IR spectrometer (Beaconsfield, UK) by direct
sampling of the compounds and the results were expressed in
wave numbers (cm1). Mass Spectra (MS) data were collected with
a Waters Micromass ZQ LC-MS Spectrometer (Milford, MA, USA)
instrument using the ESI (+) method. 1H NMR spectra were taken
on a Varian Mercury 400, a 400 MHz High Performance Digital
FT-NMR instrument (Varian, Palo Alto, CA, USA) in DMSO-d6 or
CDCl3 using TMS as internal standard. All chemical shift values
were recorded as d (ppm). Splitting patterns were as follows: s, sin-
glet; d, doublet; dd, doublet of doublet; t, triplet; m, multiplet.
Compound purity was checked by thin-layer chromatography on
silica-gel-coated aluminum sheets (Merck, 1.005554, silica gel
HF254–361, Type 60, 0.25 mm; Merck, Darmstadt, Germany). Ele-
mentary analyses of the resulting compounds were performed
with Leco CHNS 932 analyzer at Ankara University, Faculty of Phar-
macy Central II Laboratory and data were determined within ±0.4%
of the theoretical values. Microwave synthesis reactions were car-
ried out using a Milestone Microsynth LabStation 1600W (Monroe,
CT, USA).
4.1.1. Synthesis procedure of 4-amino-3-aryl-1,2,4-triazole-5-
thiones (1–3)
A mixture of equimolar amounts of aralkyl carboxylic acid
(ibuprofen/naproxen/flurbiprofen) (10 mmol) and thiocarbohy-
drazide (10 mmol) was heated in an oil bath at 160–170 C for
1 h. The resulting melted mass was triturated with hot water to
obtain the compounds. The products were purified with column
chromatography (n-hexane/ethyl acetate) (70:30).
4.1.1.1. 4-Amino-3-[1-[4-(2-methylpropyl)phenyl]ethyl]-1,2,4-
triazole-5-thione (1). Yield 0.95 g, 34%. Mp: 161–163 C (146–
148 C38). IR: mmax: 3292 (NAH), 1632 (C@N), 1167 (C@S) cm1;
1H NMR (DMSO-d6) d 0.89 (6H, d, J = 6.4 Hz, (CH3)2-CH–), 1.52
(3H, d, J = 7.2 Hz, CH3-CH–), 1.58 (2H, s, –NH2), 1.82–1.85 (1H, m,
(CH3)2-CH-CH2–), 2.43 (2H, d, J = 6.8 Hz, –CH-CH2–), 3.59 (1H, q,
J = 7.0 Hz, CH3-CH–), 7.09–7.20 (4H, m, arom.), 8.00 (1H, d,
J = 12.4 Hz, NH); MS (ESI+) m/z calcd for C14H21N4S (M+H)+
277.15, found: 277.10; Anal. Calcd for C14H20N4S: C, 60.84; H,
7.29; N, 20.27; S, 11.60. Found: C, 61.08; H, 7.56; N, 20.19; S, 11.49.
4.1.1.2. 4-Amino-3-[1-(6-methoxynaphtalen-2-yl)ethyl]-1,2,4-
triazole-5-thione (2). Yield 1.62 g, 54%. Mp: 216–218 C
(150–152 C38). IR: mmax: 3293 (NAH), 1634 (C@N), 1167 (C@S)
cm1; 1H NMR (DMSO-d6) d 1.61 (3H, d, J = 7.2 Hz, CH3-CH–), 3.85
(3H, s, OCH3), 4.48 (1H, q, J = 7.2 Hz, CH3-CH–), 5.44 (2H, s, –NH2),
7.14 (1H, dd, J = 8.8, 2.8 Hz, arom.), 7.29 (1H, d, J = 2.8 Hz, arom.),
7.39 (1H, dd, J = 8.2, 2.0 Hz, arom.), 7.78 (3H, t, J = 8.8 Hz, arom.),
13.62 (1H, s, NH); MS (ESI+) m/z calcd for C15H17N4OS (M+H)+
301.11, found: 301.13; Anal. Calcd for C15H16N4OS.1/4 CH3(C = O)
OC2H5: C, 59.61; H, 5.63; N, 17.38; S, 9.94. Found: C, 60.02; H, 5.70;
N, 16.96; S, 9.51.
4.1.1.3. 4-Amino-3-[1-(2-fluoro-1,10-biphenyl-4-yl)ethyl]-1,2,4-
triazole-5-thione (3). Yield 1.20 g, 38%. Mp: 205–207 C (169–
170 C38). IR: mmax: 3259 (NAH), 1621 (C@N), 1153 (C@S) cm1;
1H NMR (DMSO-d6) d 1.64 (3H, d, J = 7.2 Hz, CH3-CH–), 3.73 (1H,q, J = 6.4 Hz, CH3-CH–), 4.47 (2H, s, –NH2), 7.07–7.18 (2H, m,
arom.), 7.35–7.53 (6H, m, arom.), 10.96 (1H, s, NH); MS (ESI+) m/
z calcd for C16H16FN4S (M+H)+ 315.11, found: 315.11; Anal. Calcd
for C16H15FN4S: C, 61.13; H, 4.81; N, 17.82; S, 10.20. Found: C,
60.77; H, 5.07; N, 17.54; S, 9.88.
4.1.2. Synthesis procedures of 3,6-disubstituted-1,2,4-triazolo
[3,4-b]1,3,4-thiadiazines (1a–3j).
Conventional method: Compounds 1–3 (1 mmol) and corre-
sponding phenacyl halogens (1 mmol) were mixed in 20 mL of
ethanol and refluxed. Reactions ended under control of TLC. The
mixtures were then cooled to room temperature and precipitated
with a hydroxylamine hydrochloride solution. Precipitates were
purified with crystallization or column chromatography (chloro-
form/acetone).
Microwave irradiation: Compounds 1–3 (1 mmol) and corre-
sponding phenacyl halogens (1 mmol) were mixed in 10 mL of
ethanol and refluxed under irradiation (350 Watt) for adequate
durations. The mixtures were then cooled to room temperature
and precipitated with hydroxylamine hydrochloride solution. Pre-
cipitates purified with crystallization from ethanol.
4.1.2.1. 3-[1-[4-(2-Methylpropyl)phenyl]ethyl]-6-phenyl-7H-1,2,4-
triazolo[3,4-b]-1,3,4-thiadiazine (1a). Yield 0.22 g, 59% (0.18 g,
48% for MW). Mp: 143–144 C. IR: mmax: 1600 (C@N), 1310 (CAN)
cm1; 1H NMR (DMSO-d6) d 0.82 (6H, d, J = 6.8 Hz, (CH3)2-CH–),
1.67 (3H, d, J = 7.2 Hz, CH3-CH–), 1.76–1.79 (1H, m, (CH3)2-CH-
CH2–), 2.38 (2H, d, J = 6.8 Hz, –CH-CH2–), 4.29 (1H, d, J = 16.0 Hz,
–S-CH2), 4.40 (1H, d, J = 15.6 Hz, –S-CH2), 4.54 (1H, q, J = 6.8 Hz,
CH3-CH–), 7.10 (2H, d, J = 8.0 Hz, arom. H-2, H-6), 7.23 (2H, d,
J = 8.0 Hz, arom. H-3, H-5), 7.51–7.61 (3H, m, arom. H-30,40,50),
7.89 (2H, d, J = 7.6 Hz, arom. H-20, H-60); MS (ESI+) m/z calcd for
C22H25N4S (M+H)+ 377.18, found: 377.19; Anal. Calcd for
C22H24N4S: C, 70.18; H, 6.42; N, 14.88; S, 8.52. Found: C, 70.31;
H, 6.30; N, 14.83; S, 8.61.4.1.2.2. 3-[1-[4-(2-Methylpropyl)phenyl]ethyl]-6-(4-fluorophenyl)-
7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine (1b). Yield 0.35 g, 89%
(0.22 g, 57% for MW). Mp: 148–150 C. IR: mmax: 1600 (C@N),
1313 (CAN) cm1; 1H NMR (DMSO-d6) d 0.82 (6H, d, J = 6.8 Hz,
(CH3)2-CH–), 1.67 (3H, d, J = 7.6 Hz, CH3-CH–), 1.76–1.79 (1H, m,
(CH3)2-CH-CH2–), 2.38 (2H, d, J = 6.8 Hz, –CH-CH2–), 4.29 (1H, d,
J = 15.6 Hz, –S-CH2), 4.39 (1H, d, J = 16.0 Hz, –S-CH2), 4.54 (1H, q,
J = 6.8 Hz, CH3-CH–), 7.10 (2H, d, J = 8.4 Hz, arom. H-2, H-6), 7.23
(2H, d, J = 7.6 Hz, arom. H-3, H-5), 7.40 (2H, t, J = 8.8 Hz, arom.
H-30, H-50), 7.95–7.99 (2H, m, arom. H-20, H-60); MS (ESI+)m/z calcd
for C22H24FN4S (M+H)+ 395.17, found: 395.19; Anal. Calcd for
C22H23FN4S: C, 66.98; H, 5.88; N, 14.20; S, 8.13. Found: C, 66.84;
H, 5.67; N, 14.08; S, 8.26.
4.1.2.3. 3-[1-[4-(2-Methylpropyl)phenyl]ethyl]-6-(4-chlorophe-
nyl)-7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine (1c). Yield 0.29 g,
70% (0.34 g, 81% for MW). Mp: 158–159 C. IR: mmax: 1592 (C@N),
1321 (CAN) cm1; 1H NMR (DMSO-d6) d 0.81 (6H, d, J = 6.4 Hz,
(CH3)2-CH–), 1.67 (3H, d, J = 7.6 Hz, CH3-CH–), 1.76–1.79 (1H, m,
(CH3)2-CH-CH2–), 2.38 (2H, d, J = 6.8 Hz, –CH-CH2–), 4.29 (1H, d,
J = 15.6 Hz, –S-CH2), 4.39 (1H, d, J = 15.6 Hz, –S-CH2), 4.53 (1H, q,
J = 6.8 Hz, CH3-CH–), 7.09 (2H, d, J = 8.4 Hz, arom. H-2, H-6), 7.23
(2H, d, J = 7.6 Hz, arom. H-3, H-5), 7.62 (2H, d, J = 8.8 Hz, arom.
H-20, H-60), 7.92 (2H, d, J = 8.8 Hz, arom. H-30, H-50); MS (ESI+) m/z
calcd for C22H24ClN4S (M+H)+ 411.14, found: 411.18; Anal. Calcd
for C22H23ClN4S: C, 64.30; H, 5.64; N, 13.63; S, 7.80. Found: C,
64.16; H, 5.74; N, 13.38; S, 7.77.
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phenyl)-7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine (1d). Yield
0.37 g, 83% (0.15 g, 34% for MW). Mp: 150–151 C. IR: mmax: 1583
(C@N), 1311 (CAN) cm1; 1H NMR (CDCl3) d 0.88 (6H, d, J = 6.4 Hz,
(CH3)2-CH–), 1.80 (3H, d, J = 6.8 Hz, CH3-CH–), 1.83–1.87 (1H, m,
(CH3)2-CH-CH2–), 2.44 (2H, d, J = 7.2 Hz, –CH-CH2–), 3.72 (1H, d,
J = 15.6 Hz, –S-CH2), 3.85 (1H, d, J = 15.2 Hz, –S-CH2), 4.44 (1H, q,
J = 7.6 Hz, CH3-CH–), 7.07 (2H, d, J = 8.0 Hz, arom. H-2, H-6), 7.20
(2H, t, J = 7.6 Hz, arom. H-50, H-60), 7.33–7.35 (2H, m, arom. H-3, H-
5), 7.51 (1H, d, J = 2.0 Hz, arom H-30); MS (ESI+)m/z calcd for C22H23-
Cl2N4S (M+H)+ 445.10, found: 445.16; Anal. Calcd for C22H22Cl2N4S: C,
59.33; H, 4.98; N, 12.58; S, 7.20. Found: C, 59.58; H, 4.76; N, 12.75; S,
7.28.
4.1.2.5. 3-[1-[4-(2-Methylpropyl)phenyl]ethyl]-6-(4-bromophenyl)-
7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine (1e). Yield 0.27 g, 58%
(0.34 g, 73% for MW). Mp: 159–160 C. IR: mmax: 1586 (C@N), 1321
(CAN) cm1; 1H NMR (CDCl3) d 0.86 (6H, d, J = 6.8 Hz, (CH3)2-CH–),
1.78–1.84 (1H, m, (CH3)2-CH-CH2–), 1.82 (3H, d, J = 7.6 Hz, CH3-CH–),
2.41 (2H, d, J = 7.2 Hz, –CH-CH2–), 3.77 (1H, d, J = 15.6 Hz, –S-CH2),
3.90 (1H, d, J = 15.6 Hz, –S-CH2), 4.49 (1H, q, J = 7.2 Hz, CH3-CH–),
7.06 (2H, d, J = 8.0 Hz, arom. H-2, H-6), 7.24 (2H, d, J = 8.0 Hz, arom.
H-3, H-5), 7.61 (4H, s, arom. H-20, H-30, H-50, H-60); MS (ESI+)m/z calcd
for C22H24BrN4S (M+H)+ 455.09, found: 455.15; Anal. Calcd for C22H23
BrN4S: C, 58.02; H, 5.09; N, 12.30; S, 7.04. Found: C, 57.73; H, 5.09; N,
12.29; S, 7.24.
4.1.2.6. 3-[1-[4-(2-Methylpropyl)phenyl]ethyl]-6-(4-nitrophenyl)-
7H-1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazine (1f). Yield 0.36 g,
84% (0.34 g, 80% for MW). Mp: 152–153 C. IR: mmax: 1600 (C@N),
1347 (CAN) cm1; 1H NMR (CDCl3) d 0.86 (6H, d, J = 6.8 Hz,
(CH3)2-CH–), 1.79–1.81 (1H, m, (CH3)2-CH-CH2–), 1.84 (3H, d,
J = 7.6 Hz, CH3-CH–), 2.42 (2H, d, J = 6.8 Hz, –CH-CH2–), 3.86 (1H,
d, J = 15.6 Hz, –S-CH2), 3.98 (1H, d, J = 15.2 Hz, –S-CH2), 4.49 (1H,
q, J = 7.2 Hz, CH3-CH–), 7.08 (2H, d, J = 8.4 Hz, arom. H-2, H-6),
7.23 (2H, d, J = 7.6 Hz, arom. H-3, H-5), 7.90 (2H, d, J = 8.8 Hz, arom.
H-20, H-60), 8.33 (2H, d, arom. J = 8.8 Hz, H-30, H-50); MS (ESI+) m/z
calcd for C22H24N5O2S (M+H)+ 422.17, found: 422.20; Anal. Calcd
for C22H23N5O2S: C, 62.69; H, 5.50; N, 16.61; S, 7.61. Found: C,
62.36; H, 5.53; N, 16.53; S, 7.57.
4.1.2.7. 3-[1-[4-(2-Methylpropyl)phenyl]ethyl]-6-(4-methylphe-
nyl)-7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine (1g). Yield
0.1 g, 25% (0.31 g, 77% for MW). Mp: 185–186 C. IR: mmax: 1598
(C@N), 1316 (CAN) cm1; 1H NMR (CDCl3) d 0.86 (6H, d,
J = 6.8 Hz, (CH3)2-CH–), 1.79–1.84 (1H, m, (CH3)2-CH-CH2–), 1.83
(3H, d, J = 7.6 Hz, CH3-CH–), 2.41 (2H, d, J = 7.6 Hz, –CH-CH2–),
2.43 (3H, s, –CH3), 3.77 (1H, d, J = 15.6 Hz, –S-CH2), 3.91 (1H, d,
J = 15.2 Hz, –S-CH2), 4.52 (1H, q, J = 7.6 Hz, CH3-CH–), 7.06 (2H, d,
J = 7.6 Hz, arom. H-2, H-6), 7.27 (4H, m, arom. H-3, H-5, H-30, H-
50), 7.66 (2H, d, J = 8.0 Hz, arom. H-20, H-60); MS (ESI+) m/z calcd
for C23H27N4S (M+H)+ 391.20, found: 391.20, Anal. Calcd for
C23H26N4S.H2O: C, 67.62; H, 6.91; N, 13.71; S, 7.85. Found: C,
67.92; H, 6.44; N, 14.27; S, 7.87.4.1.2.8. 3-[1-[4-(2-Methylpropyl)phenyl]ethyl]-6-(4-methoxyphe-
nyl)-7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine (1h). Yield 0.19 g,
46% (0.22 g, 52% for MW). Mp: 184–185 C. IR: mmax: 1605 (C@N),
1316 (CAN), 1256 (CAO) cm1; 1H NMR (CDCl3) d 0.86 (6H, d,
J = 6.8 Hz, (CH3)2-CH–), 1.79–1.81 (1H, m, (CH3)2-CH-CH2–), 1.82
(3H, d, J = 7.6 Hz, CH3-CH–), 2.40 (2H, d, J = 7.2 Hz, –CH-CH2–),
3.75 (1H, d, J = 15.2 Hz, –S-CH2), 3.90 (1H, d, J = 14.0 Hz, –S-CH2),
3.88 (3H, s, -OCH3), 4.52 (1H, q, J = 7.2 Hz, CH3-CH–), 6.97 (2H, d,
J = 8.8 Hz, arom. H-30, H-50), 7.06 (2H, d, J = 7.6 Hz, arom. H-2,H-6), 7.26 (2H, d, J = 7.6 Hz, arom. H-3, H-5), 7.73 (2H, d,
J = 8.8 Hz, arom. H-20, H-60); 13C NMR (CDCl3) d 20.06 (CH3-CH–),
22.05 ((CH3)2CH–), 22.39 ((CH3)2-CH-CH2–), 29.47 (–CH-CH2–),
35.11 (–SCH2–), 44.09 (CH3-CH–), 55.44 (–OCH3), 114.31 (arom.
C-30, C-50), 125.47 (arom. C-4), 126.98 (arom. C-2, C-6), 128.96
(arom. C-3, C-5), 129.13 (arom. C-10), 139.37 (arom. C-1), 139.45
(arom. C-20, C-60), 153.66 (arom. C-40), 140.19 (C-8a), 155.57 (C-
3), 162.08 (C-6); MS (ESI+) m/z calcd for C23H27N4OS (M+H)+
407.19, found: 407.22; Anal. Calcd for C23H26N4OS: C, 67.95; H,
6.45; N, 13.78; S, 7.89. Found: C, 68.09; H, 6.65; N, 13.39; S, 7.75.
4.1.2.9. 3-[1-[4-(2-Methylpropyl)phenyl]ethyl]-6-(4-trifluo-
romethylphenyl)-7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine (1i).
Yield 0.15 g, 32% (0.29 g, 61% for MW). Mp: 176–178 C. IR: mmax:
1618 (C@N), 1310 (CAN) cm1; 1H NMR (CDCl3) d 0.86 (6H, d,
J = 6.8 Hz, (CH3)2-CH–), 1.81 (1H, m, (CH3)2-CH-CH2–), 1.92 (3H, d,
J = 6.8 Hz, CH3-CH–), 2.43 (2H, d, J = 7.2 Hz, –CH-CH2–), 4.30 (1H, q,
CH3-CH–), 4.70 (2H, d, J = 6.8 Hz, –S-CH2), 7.12 (2H, d, J = 8.0 Hz, H-2,
H-6), 7.28 (2H, d, J = 8.0 Hz, H-3, H-5), 7.78 (2H, d, J = 8.0 Hz, H-20, H-
60), 7.98 (2H, d, J = 8.0 Hz, H-30, H-50); MS (ESI+) m/z calcd for C23-
H24F3N4S (M+H)+ 445.17, found: 445.14; Anal. Calcd for C23H23F3N4S:




(1j). Yield 0.12 g, 27% (0.29 g, 65% for MW). Mp: 132–133 C.
IR: mmax: 1596 (C@N), 1362 (CAN), 1297 (CAO) cm1; 1H NMR
(CDCl3) d 0.86 (6H, d, J = 6.4 Hz, (CH3)2-CH–), 1.79–1.82 (1H, m,
(CH3)2-CH-CH2–), 1.83 (3H, d, J = 7.2 Hz, CH3-CH–), 2.42 (2H, d,
J = 7.2 Hz, –CH-CH2–), 3.79 (1H, d, J = 15.6 Hz, –S-CH2), 3.92 (1H,
d, J = 15.6 Hz, –S-CH2), 4.49 (1H, q, J = 6.8 Hz, CH3-CH–), 7.07 (2H,
d, J = 8.0 Hz, arom. H-2, H-6), 7.24 (2H, d, J = 7.6 Hz, arom. H-3,
H-5), 7.32 (2H, d, J = 7.6 Hz, arom. H-20, H-60), 7.78 (2H, d,
J = 8.8 Hz, arom. H-30, H-50); MS (ESI+) m/z calcd for C23H24F3N4OS
(M+H)+ 461.16, found: 461.16; Anal. Calcd for C23H23F3N4OS.1/4
H2O C, 59.41; H, 5.09; N, 12.05; S, 6.89. Found: C, 59.32; H, 4.74;
N, 12.13; S, 6.92.
4.1.2.11. 3-[1-(6-Methoxynaphtalen-2-yl)ethyl]-6-phenyl-7H-
1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine (2a). Yield 0.31 g, 77%
(0.21 g, 52% for MW). Mp: 199–200. IR: mmax: 1605 (C@N), 1308
(CAN), 1262 (CAO) cm1; 1H NMR (DMSO-d6) d 1.77 (3H, d,
J = 7.2 Hz, CH3-CH–), 3.84 (3H, s, OCH3), 4.26 (1H, d, J = 15.6 Hz, –
S-CH2), 4.39 (1H, d, J = 16.0 Hz, –S-CH2), 4.71 (1H, q, J = 7.2 Hz,
CH3-CH–), 7.13 (1H, dd, J = 9.2, 2.4 Hz, arom. H), 7.26 (1H, s, arom.
H), 7.44–7.58 (4H, m, arom. H), 7.78 (3H, t, J = 9.6 Hz, arom. H-30,
H-40, H-50), 7.90 (2H, d, J = 7.2 Hz, arom. H-20, H-60); MS (ESI+) m/z
calcd for C23H21N4OS (M+H)+ 401.14, found: 401.17; Anal. Calcd
for C23H20N4OS: C, 68.98; H, 5.03; N, 13.99; S, 8.01. Found: C,
69.42; H, 5.12; N, 13.94; S, 8.13.4.1.2.12. 3-[1-(6-Methoxynaphtalen-2-yl)ethyl]-6-(4-fluorophenyl)-
7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine (2b). Yield 0.39 g,
92% (0.20 g, 47% for MW). Mp.: 187–189 C. IR: mmax: 1603
(C@N), 1303 (CAN), 1261 (CAO) cm1; 1H NMR (DMSO-d6) d
1.76 (3H, d, J = 6.8 Hz, CH3-CH–), 3.84 (3H, s, OCH3), 4.25 (1H, d,
J = 16.0 Hz, –S-CH2), 4.39 (1H, d, J = 16.0 Hz, –S-CH2), 4.71 (1H, q,
J = 6.8 Hz, CH3-CH–), 7.13 (1H, dd, J = 8.8, 2.8 Hz, arom.H), 7.26
(1H, s, arom. H), 7.36–7.47 (3H, m, arom. H), 7.78 (3H, t,
J = 9.2 Hz, arom. H), 7.96–8.00 (2H, m, arom. H-20, H-60); MS (ESI
+) m/z calcd for C23H19FN4OS (M+H)+ 441.12, found 441.17; Anal.
Calcd for C23H19FN4OS: C, 66.01; H, 4.58; N, 13.39; S, 7.66. Found:
C, 66.16; H, 4.42; N, 13.26; S, 7.71.
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nyl)-7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine (2c). Yield
0.10 g, 25% (0.36 g, 90% for MW). Mp: 160–161 C. IR: mmax: 1603
(C@N), 1303 (CAN), 1264 (CAO) cm1; 1H NMR (DMSO-d6) d
1.77 (3H, d, J = 7.2 Hz, CH3-CH–), 3.84 (3H, s, OCH3), 4.25 (1H, d,
J = 16 Hz, –S-CH2), 4.39 (1H, d, J = 15.6 Hz, –S-CH2), 4.70 (1H, q,
J = 7.2 Hz, CH3-CH–), 7.13 (1H, dd, J = 8.8, 2.8 Hz, arom.H), 7.26
(1H, s, arom.H), 7.45 (1H, dd, J = 8.4, 1.6 Hz, arom.H), 7.61 (2H, d,
J = 8.4 Hz, H-20, H-60) 7.75–7.81 (3H, m, arom.H), 7.93 (2H, d,
J = 8.8 Hz, H-30, H-50); MS (ESI+) m/z calcd for C23H20ClN4OS (M
+H)+ 435.11, found 435.15; Anal. Calcd for C23H19ClN4OS: C,
63.51; H, 4.40; N, 12.88; S, 7.37. Found: C, 63.57; H, 4.49; N,
12.99; S, 7.14.4.1.2.14. 3-[1-(6-Methoxynaphtalen-2-yl)ethyl]-6-(2,4-dichloro-
phenyl)-7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine (2d). Yield
0.30 g, 64% (0.28 g, 59% for MW). Mp: 178–179 C. IR: mmax: 1608
(C@N), 1315 (CAN), 1266 (CAO) cm1; 1H NMR (CDCl3) d 1.89
(3H, d, J = 7.2 Hz, CH3-CH–), 3.66 (1H, d, J = 15.6 Hz, –S-CH2), 3.82
(1H, d, J = 15.2 Hz, –S-CH2), 3.91 (3H, s, OCH3), 4.59 (1H, q,
J = 7.6 Hz, CH3-CH–), 7.06 (1H, d, J = 8.0 Hz, arom. H), 7.10 (1H, d,
J = 2.4 Hz, arom. H), 7.15 (1H, dd, J = 8.8, 2.4 Hz, arom. H), 7.26
(1H, dd, J = 8.0, 2.0 Hz, arom. H), 7.41 (1H, dd, J = 9.2, 2.0 Hz, arom.
H), 7.48 (1H, d, J = 2.4 Hz, arom. H), 7.66–7.69 (3H,m, arom. H-30, H-
50); MS (ESI+) m/z calcd for C23H19Cl2N4OS (M+H)+ 469.07, found
469.11; Anal. Calcd for C23H18Cl2N4OS: C, 58.85; H, 3.87; N, 11.94;
S, 6.83. Found: C, 58.75; H, 3.87; N, 11.88; S, 6.73.
4.1.2.15. 3-[1-(6-Methoxynaphtalen-2-yl)ethyl]-6-(4-bromophe-
nyl)-7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine (2e). Yield
0.05 g, 11% (0.19 g, 41% for MW). Mp: 166–168 C. IR: mmax: 1607
(C@N), 1319 (CAN), 1264 (CAO) cm1; 1H NMR (DMSO-d6) d
1.76 (3H, d, J = 7.2 Hz, CH3-CH–), 3.84 (3H, s, OCH3), 4.25 (1H, d,
J = 16.0 Hz, –S-CH2), 4.38 (1H, d, J = 15.6 Hz, –S-CH2), 4.70 (1H, q,
J = 6.8 Hz, CH3-CH–), 7.13 (1H, dd, J = 9.2, 2.8 Hz, arom. H), 7.26
(1H, s, arom. H), 7.45 (1H, dd, J = 8.0, 2.0 Hz, arom. H), 7.73–7.86
(7H, m, arom. H); MS (ESI+) m/z calcd for C23H20BrN4OS (M+H)+
479.05, found 479.11; Anal. Calcd for C23H19BrN4OS: C, 57.63; H,
3.99; N, 11.69; S, 6.69. Found: C, 57.64; H, 4.20; N, 11.55; S, 6.50.
4.1.2.16. 3-[1-(6-Methoxynaphtalen-2-yl)ethyl]-6-(4-nitrophenyl)-
7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine (2f). Yield 0.11 g,
24% (0.28 g, 60% for MW). Mp: 108–110 C. IR: mmax: 1605 (C@N),
1314 (CAN), 1265 (CAO) cm1; 1H NMR (CDCl3) d 1.92 (3H, d,
J = 7.2 Hz, CH3-CH–), 3.79 (1H, d, J = 15.6 Hz, –S-CH2), 3.89 (3H, s,
OCH3), 3.94 (1H, d, J = 16.0 Hz, –S-CH2), 4.65 (1H, q, J = 7.2 Hz,
CH3-CH–), 7.08–7.15 (2H, m, arom. H), 7.44 (1H, dd, J = 8.4, 2.0 Hz,
arom. H), 7.67 (3H, t, J = 7.2 Hz, arom. H), 7.86 (2H, d, J = 8.8 Hz,
arom. H20, H-60), 8.29 (2H, d, J = 9.2 Hz, arom. H-30, H-50); MS (ESI
+) m/z calcd for C23H20N5O3S (M+H)+ 446.13, found 446.17; Anal.
Calcd for C23H19N5O3S: C, 62.01; H, 4.30; N, 15.72; S, 7.20. Found:
C, 62.07; H, 4.34; N, 15.69; S, 7.03.
4.1.2.17. 3-[1-(6-Methoxynaphtalen-2-yl)ethyl]-6-(4-methylphe-
nyl)-7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine (2g). Yield
0.11 g, 26% (0.20 g, 48% for MW). Mp: 169–171 C. IR: mmax: 1605
(C@N), 1309 (CAN), 1263 (CAO) cm1; 1H NMR (CDCl3) d 1.91
(3H, d, J = 7.6 Hz, CH3-CH–), 2.42 (3H, s, –CH3), 3.71 (1H, d,
J = 15.6 Hz, –S-CH2), 3.89 (1H, d, J = 15.2 Hz, –S-CH2), 3.89 (3H, s, –
OCH3), 4.68 (1H, q, J = 7.6 Hz, CH3-CH–), 7.08–7.13 (2H, m, arom.
H), 7.26 (2H, d, J = 8.4 Hz, arom.H), 7.48 (1H, dd, J = 8.4, 2.0 Hz,
arom.H), 7.62–7.74 (5H, m, arom.H); MS (ESI+)m/z calcd for C24H23-
N4OS (M+H)+ 415.16, found 415.16; Anal. Calcd for C24H22N4-
OS1/4H2O: C, 68.79; H, 5.41; N, 13.37; S, 7.65. Found: C, 68.75; H,
5.23; N, 13.01; S, 7.49.4.1.2.18. 3-[1-(6-Methoxynaphtalen-2-yl)ethyl]-6-(4-methoxy-
phenyl)-7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine (2h). Yield
0.21 g, 49% (0.29 g, 67% for MW). Mp: 121–122 C. IR: mmax: 1606
(C@N), 1316 (CAN), 1257 (CAO) cm1; 1H NMR (CDCl3) d 1.91 (3H,
d, J = 7.6 Hz, CH3-CH–), 3.69 (1H, d, J = 15.6 Hz, –S-CH2), 3.86 (1H, d,
J = 15.6 Hz, –S-CH2), 3.88 (6H, s, -OCH3), 4.68 (1H, q, J = 7.2 Hz, CH3-
CH–), 6.95 (2H, d, J = 8.8 Hz, arom. H), 7.08–7.13 (2H, m, arom. H),
7.47 (1H, dd, J = 8.0, 2.0 Hz, arom. H), 7.66–7.73 (5H, m, arom. H);
MS (ESI+) m/z calcd for C24H23N4O2S (M+H)+ 431.15, found 431.20;
Anal. Calcd for C24H22N4O2S: C, 66.96; H, 5.15; N, 13.01; S, 7.45.
Found: C, 67.03; H, 5.37; N, 12.81; S, 7.33.
4.1.2.19. 3-[1-(6-Methoxynaphtalen-2-yl)ethyl]-6-(4-trifluoro
methylphenyl)-7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine (2i).
Yield 0.18 g, 37% (0.29 g, 59% for MW). Mp: 149–150 C. IR: mmax:
1607 (C@N), 1314 (CAN), 1269 (CAO) cm1; 1H NMR (CDCl3) d 1.78
(3H, d, J = 7.2 Hz, CH3-CH–), 3.84 (3H, s, -OCH3), 4.32 (1H, d,
J = 15.6 Hz, –S-CH2), 4.44 (1H, d, J = 16.0 Hz, –S-CH2), 4.71 (1H, q,
J = 7.6 Hz, CH3-CH–), 7.13 (1H, dd, J = 8.8, 2.8 Hz, arom. H), 7.26
(1H, d, J = 2.8 Hz, arom. H), 7.46 (1H, dd, J = 8.4, 2.0 Hz, arom. H),
7.76–7.82 (3H, m, arom. H), 7.91 (2H, d, J = 8.4 Hz, arom. H), 8.10
(2H, d, J = 8.0 Hz, arom. H); MS (ESI+) m/z calcd for C24H20F3N4OS
(M+H)+ 469.13, found 469.04; Anal. Calcd for C24H19F3N4OS: C,




Yield 0.19 g, 39% (0.35 g, 72% for MW). Mp: 139–140 C. IR: mmax:
1606 (C@N), 1322 (CAN), 1255 (CAO) cm1; 1H NMR (CDCl3) d 1.91
(3H, d, J = 7.2 Hz, CH3-CH–), 3.73 (1H, d, J = 15.6 Hz, –S-CH2), 3.89
(1H, d, J = 15.2 Hz, –S-CH2), 3.89 (3H, s, -OCH3), 4.66 (1H, q,
J = 7.2 Hz, CH3-CH–), 7.08–7.14 (2H, m, arom.H), 7.29 (2H, d,
J = 8.0 Hz, arom.H), 7.45 (1H, dd, J = 8.0, 2.0 Hz, arom.H), 7.65–7.76
(5H, m, arom.H); MS (ESI+) m/z calcd for C24H20F3N4O2S (M+H)+
485.13, found 485.12; Anal. Calcd for C24H19F3N4O2S: C, 59.50; H,
3.95; N, 11.56; S, 6.62. Found: C, 59.56; H, 4.16; N, 11.63; S, 6.53.
4.1.2.21. 3-[1-(2-Fluoro-1,10-biphenyl-4-yl)ethyl]-6-phenyl-7H-
1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine (3a). Yield 0.15 g,
36% (0.24 g, 57% for MW). Mp: 131–133 C. IR: mmax: 1583 (C@N),
1319 (CAN) cm1; 1H NMR (CDCl3) d 1.88 (3H, d, J = 7.6 Hz, CH3-
CH–), 3.85 (1H, d, J = 15.6 Hz, –S-CH2), 3.97 (1H, d, J = 15.2 Hz, –
S-CH2), 4.59 (1H, q, J = 6.8 Hz, CH3-CH–), 7.18–7.24 (2H, m, arom.
H), 7.34–7.56 (9H, m, arom. H), 7.78–7.80 (2H, m, arom. H); MS
(ESI+)m/z calcd for C24H20FN4S (M+H)+ 415.14, found 415.17; Anal.
Calcd for C24H19FN4S: C, 69.54; H, 4.62; N, 13.52; S, 7.74. Found: C,
69.22; H, 4.52; N, 13.77; S, 7.70.
4.1.2.22. 3-[1-(2-Fluoro-1,10-biphenyl-4-yl)ethyl]-6-(4-fluoro-
phenyl)-7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine (3b). Yield
0.32 g, 74% (0.28 g, 63% for MW). Mp: 175–176 C. IR: mmax: 1600
(C@N), 1318 (CAN) cm1; 1H NMR (CDCl3) d 1.87 (3H, d, J = 7.6 Hz,
CH3-CH–), 3.83 (1H, d, J = 15.6 Hz, –S-CH2), 3.94 (1H, d, J = 15.6 Hz,
–S-CH2), 4.57 (1H, q, J = 7.6 Hz, CH3-CH–), 7.16–7.22 (4H, m, arom.
H), 7.35–7.51 (6H, m, arom. H), 7.78–7.82 (2H, m, arom. H); MS
(ESI+) m/z calcd for C24H19F2N4S (M+H)+ 433.13, found 433.17;
Anal. Calcd for C24H18F2N4S: C, 66.65; H, 4.20; N, 12.95; S, 7.41.
Found: C, 66.66; H, 4.06; N, 12.98; S, 7.30.
4.1.2.23. 3-[1-(2-Fluoro-1,10-biphenyl-4-yl)ethyl]-6-(4-chloro-
phenyl)-7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine (3c). Yield
0.41 g, 90% (0.29 g, 63% for MW). Mp: 199–200 C. IR: mmax: 1591
(C@N), 1321 (CAN) cm1; 1H NMR (CDCl3) d 1.86 (3H, d,
J = 7.2 Hz, CH3-CH–), 3.82 (1H, d, J = 15.6 Hz, –S-CH2), 3.93 (1H, d,
J = 15.6 Hz, –S-CH2), 4.56 (1H, q, J = 7.6 Hz, CH3-CH–), 7.15–7.21
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arom. H); MS (ESI+) m/z calcd for C24H19FClN4S (M+H)+ 449.10,
found 449.15; Anal. Calcd for C24H18FClN4S: C, 64.21; H, 4.04; N,
12.48; S, 7.14. Found: C, 64.23; H, 3.92; N, 12.57; S, 7.05.
4.1.2.24. 3-[1-(2-Fluoro-1,10-biphenyl-4-yl)ethyl]-6-(2,4-dichlo-
rophenyl)-7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine (3d). Yield
0.38 g, 79% (0.24 g, 50% for MW). Mp: 182–183 C. IR: mmax: 1583
(C@N), 1303 (CAN) cm1; 1H NMR (CDCl3) d 1.85 (3H, d, J = 6.8 Hz,
CH3-CH–), 3.79 (1H, d, J = 15.6 Hz, –S-CH2), 3.88 (1H, d, J = 15.6 Hz,
–S-CH2), 4.51 (1H, q, J = 6.8 Hz, CH3-CH–), 7.13–7.19 (2H, m, arom.
H), 7.28–7.46 (6H, m, arom. H), 7.51–7.53 (3H, m, arom. H-30, H-50,
H-60); MS (ESI+) m/z calcd for C24H18FCl2N4S (M+H)+ 483.06, found
483.10; Anal. Calcd for C24H17FCl2N4S: C, 59.63; H, 3.54; N, 11.59;
S, 6.63. Found: C, 59.84; H, 3.43; N, 11.92; S, 6.71.
4.1.2.25. 3-[1-(2-Fluoro-1,10-biphenyl-4-yl)ethyl]-6-(4-bromo-
phenyl)-7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine (3e). Yield
0.34 g, 68% (0.30 g, 60% for MW). Mp: 196–197 C. IR: mmax: 1585
(C@N), 1322 (CAN) cm1; 1H NMR (CDCl3) d 1.87 (3H, d, J = 7.2 Hz,
CH3-CH–), 3.83 (1H, d, J = 15.6 Hz, –S-CH2), 3.94 (1H, d, J = 15.2 Hz,
–S-CH2), 4.57 (1H, q, J = 7.6 Hz, CH3-CH–), 7.15–7.22 (2H, m, arom.
H), 7.35–7.52 (6H, m, arom. H), 7.65 (4H, s, arom. H-20, H-30, H-50,
H-60); MS (ESI+) m/z calcd for C24H19FBrN4S (M+H)+ 493.05 found
493.12; Anal. Calcd for C24H18FBrN4S: C, 58.42; H, 3.68; N, 11.36; S,
6.50. Found: C, 58.28; H, 3.70; N, 11.34; S, 6.46.
4.1.2.26. 3-[1-(2-Fluoro-1,10-biphenyl-4-yl)ethyl]-6-(4-nitro-
phenyl)-7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine (3f). Yield
0.26 g, 56% (0.19 g, 41% for MW). Mp: 174–176 C. IR: mmax: 1582
(C@N), 1322 (CAN) cm1; 1H NMR (CDCl3) d 1.88 (3H, d, J = 6.8 Hz,
CH3-CH–), 3.91 (1H, d, J = 15.6 Hz, –S-CH2), 4.01 (1H, d, J = 15.6 Hz,
–S-CH2), 4.57 (1H, q, J = 7.6 Hz, CH3-CH–), 7.14–7.21 (2H, m, arom.
H), 7.35–7.51 (6H, m, arom. H), 7.96 (2H, d, J = 9.2 Hz, arom. H-20,
H-60), 8.36 (2H, d, J = 8.8 Hz, arom. H-30, H-50); MS (ESI+) m/z calcd
for C24H19FN5O2S (M+H)+ 460.12 found 460.18; Anal. Calcd for C24-
H18FN5O2S: C, 62.73; H, 3.95; N, 15.24; S, 6.98. Found: C, 62.90; H,
3.87; N, 15.42; S, 7.11.
4.1.2.27. 3-[1-(2-Fluoro-1,10-biphenyl-4-yl)ethyl]-6-(4-methyl-
phenyl)-7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine (3g). Yield
0.15 g, 34% (0.15 g, 35% for MW). Mp: 150–151 C. IR: mmax: 1595
(C@N), 1320 (CAN) cm1; 1H NMR (CDCl3) d 1.87 (3H, d, J = 7.6 Hz,
CH3-CH–), 2.44 (3H, s, –CH3), 3.82 (1H, d, J = 15.2 Hz, –S-CH2), 3.95
(1H, d, J = 15.6 Hz, –S-CH2), 4.59 (1H, q, J = 7.2 Hz, CH3-CH–), 7.18–
7.24 (2H, m, arom. H), 7.30–7.51 (8H, m, arom.H), 7.69 (2H, d,
J = 8.4 Hz, arom. H); MS (ESI+) m/z calcd for C25H22FN4S (M+H)+
429.16 found 429.17; Anal. Calcd for C25H21FN4S.1/4 H2O: C,




0.19 g, 42% (0.24 g, 54% for MW). Mp: 240–241 C. IR: mmax: 1594
(C@N), 1320 (CAN), 1258 (CAO) cm1; 1H NMR (CDCl3) d 1.92
(3H, d, J = 6.8 Hz, CH3-CH–), 3.89 (3H, s, -OCH3), 4.14 (1H, d,
J = 15.2 Hz, –S-CH2), 4.41 (1H, d, J = 15.6 Hz, –S-CH2), 4.72 (1H, q,
J = 7.6 Hz, CH3-CH–), 7.01 (2H, d, J = 8.4 Hz, arom. H-30, H-50), 7.20–
7.51 (8H, m, arom. H), 7.86 (2H, d, J = 8.4 Hz, arom. H); MS (ESI+)
m/z calcd for C25H22FN4OS (M+H)+ 445.15 found 445.20; Anal. Calcd
for C25H21FN4OS: C, 67.55; H, 4.76; N, 12.60; S, 7.21. Found: C, 67.55;
H, 4.65; N, 12.50; S, 6.97.
4.1.2.29. 3-[1-(2-Fluoro-1,10-biphenyl-4-yl)ethyl]-6-(4-trifluoro-
methylphenyl)-7H-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine (3i).
Yield 0.16 g, 32% (0.35 g, 70% for MW). Mp: 166–167 C. IR: mmax:
1583 (C@N), 1316 (CAN) cm1; 1H NMR (CDCl3) d 2.42 (3H, d,J = 7.6 Hz, CH3-CH–), 4.42 (1H, d, J = 15.6 Hz, –S-CH2), 4.53 (1H, d,
J = 15.6 Hz, –S-CH2), 5.11 (1H, q, J = 7.2 Hz, CH3-CH–), 7.69–7.75
(2H, m, arom. H), 7.88–8.04 (6H, m, arom. H), 8.30 (2H, d, J = 8.8 Hz,
arom. H-20, H-60), 8.44 (2H, d, J = 8.0 Hz, arom. H-30, H-50); MS (ESI
+) m/z calcd for C25H19F4N4S (M+H)+ 483.13 found 483.04; Anal.
Calcd for C25H18F4N4S: C, 62.23; H, 3.76; N, 11.61; S, 6.64. Found: C,
62.23; H, 3.80; N, 11.67; S, 6.73.
4.1.2.30. 3-[1-(2-Fluoro-1,10-biphenyl-4-yl)ethyl]-6-(4-trifluo-
romethoxyphenyl)-7H-1,2,4-triazolo [3,4-b]-1,3,4-thiadiazine
(3j). Yield 0.20 g, 39% (0.18 g, 35% for MW). Mp: 170–
171 C. IR: mmax: 1597 (C@N), 1317 (CAN), 1294 (CAO) cm1; 1H
NMR (CDCl3) d 1.88 (3H, d, J = 7.2 Hz, CH3-CH–), 3.85 (1H, d,
J = 15.6 Hz, –S-CH2), 3.96 (1H, d, J = 15.2 Hz, –S-CH2), 4.57 (1H, q,
J = 7.6 Hz, CH3-CH–), 7.16–7.22 (2H, m, arom. H), 7.34–7.44 (6H,
m, arom. H), 7.50 (2H, d, J = 8.4 Hz, arom. H-20, H-60), 7.84 (2H, d,
J = 9.2 Hz, arom. H-30, H-50); MS (ESI+) m/z calcd for C25H19F4N4S
(M+H)+ 499.12 found 499.10; Anal. Calcd for C25H18F4N4OS: C,
60.24; H, 3.64; N, 11.24; S, 6.43. Found: C, 59.99; H, 3.71; N,
11.08; S, 6.51.
4.2. Pharmacology
4.2.1. Cells and culture
Human liver (Huh7, HepG2, Hep-3B, Mahlavu, FOCUS and
Snu475), breast (MCF7) and colon (HCT116) cancer cell lines were
cultured routinely at 37 C under 5% CO2 in Dulbecco’s Modified
Eagle’s Standard (DMEM) medium with 10% Fetal Bovine Serum
(FBS), 0.1 mM nonessential amino acids (NEAA), 100 units/mL
penicillin and 100 lg/mL streptomycin (Gibco, Invitrogen, Carlsbad,
CA, USA).
4.2.2. NCI-60. Sulforhodamine B assay for in vitro cytotoxicity
screening
Human liver cancer (Huh7, HepG2, Hep3B, Mahlavu, FOCUS and
Snu475), breast cancer (MCF7) and colon cancer (HCT116) cell
lines were inoculated into 96-well plates (1000–3000 cell/well)
and grown for 24 h. The cells were then treated with increasing
concentrations of the compounds (2.5–40 lM) for 72 h. Later, the
growth medium was aspirated and samples were washed with
1xPBS (CaCl2-, MgCl2-free) (Gibco, Invitrogen, Carlsbad, CA, USA)
and fixed with 10% (v/v) trichloroacetic acid (Merck, Schuchardt,
Germany) by incubation for 1 h at 4 C. Samples were then washed
five times with deionized water and left to air dry. Finally, 50 ll of
a 0.4% (m/v) of sulforhodamine (Sigma-Aldrich, St. Louis, USA) in
1% acetic acid solution was added to each well and the plates were
incubated for 10 min at room temperature. The unbound stain was
removed by washing the samples five times with 1% acetic acid
and left to air dry. The bound sulforhodamine B (Sigma–Aldrich)
was then solubilized using 10 mM Tris-base (Amresco, USA). The
absorbance values were obtained at 515 nm. All experiments were
done in triplicate. Data with R2 values between 0.8 and 1 was con-
sidered significant and standard deviations were included in the
related anti-proliferative data tables.
4.2.3. Real-time cell electronic sensing (RT-CES analysis)
To perform the cytotoxicity assessment with the real-time cell
analyzer, first 50 lL of growth medium was placed into 96 e-
plate to get a steady impedance value. Then human liver cancer
(Huh7) cells were inoculated into the 96 e-plate (1000–5000
cells/well). The attachment, spreading, and proliferation of the
cells were monitored every 30 min using the RT-CES in a cell cul-
ture incubator. 24 h after seeding, cells were treated with IC100,
IC50 and IC25 concentrations of the selected compounds. DMSO
(AppliChem Biochemica, Darmstadt, Germany) was used as a neg-
ative control. Each experiment was repeated at least three times.
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an arbitrary unit called the cell index (CI). The CI value was noted
every 10 min for the first 24 h and then every 30 min. The cell inhi-
bition rate (%) = [1  (CItreated cells/CIDMSO)]  100.
4.2.4. Immunofluorescence staining with hoechst 33258
protocol
Cells were seeded on coverslips in six-well plates. After an over-
night incubation period, cells were treated with 10 lM of com-
pounds for 48 h. To determine nuclear condensation by Hoechst
33258 (Sigma–Aldrich) staining, cells were fixed with 1 mL of cold
methanol for 10 min after being washed twice with ice-cold
1  PBS. Then the samples were incubated with 1 lg/mL of
Hoechst for 5 min in darkness. The coverslips were then rinsed
with distilled water, mounted on glass microscopic slides using
50% glycerol, and examined under fluorescent microscopy (40).
4.2.5. Fluorescence-activated cell sorting (FACS)-propidium
iodide method
Huh7 cell line was inoculated into 100-mm culture dishes
(300,000 cells/dish). After 24 h, cells were treated with 10 lM con-
centration of compounds for 24-hour and 48-hour periods. Then
cells were trypsinized and collected as cell pellets, and samples
were fixed in ice-cold 70% ethanol and stored at 20 C. Before
the analysis, the samples were stained with 500 lL propidium
iodide solution according to the manufacturer’s protocol. Cell cycle
analysis was conducted with CellQuest Software.
4.2.6. Oxidative stress assays
Huh7 and Mahlavu cells were inoculated into 96-well 100-mm
culture dishes. After 24 h, they were treated with 10 lM com-
pounds, or DMSO control for 48 h. Then cells were collected with
trypsinization and samples were prepared according to MUSE
Oxidative Assay kit (MCH100111, Millipore) manufacturer’s proto-
col and analyzed. In parallel, cells were cultured into 6-well dishes
and treated with the compounds or controls for 48 h. Then, cells
were washed with 1xPBS and stained with Dichloro-dihydro fluo-
rescein diacetate (DCFH-DA) solution (10 mM glucose, 1 mM
DCFH-DA, 10 mM HEPES dissolved in 1  PBS) for 15 min, at
37 C, in dark. Later, cells were washed three times with 1xPBS
and observed under fluorescent microscope. In both experiments,
one group of cells were grown in selenium deficient serum-free
medium as positive control for oxidative stress.41
4.2.7. Western blot experiments
Huh7 and Mahlavu cells were treated with the compounds or
with DMSO control for 24 or 48 h. 25 ng of protein was used per
well (NuPAGE). p-Akt (Ser473) (9271, Cell Signaling), Akt (9272,
Cell Signaling), p-GSK3-a/b (Ser21/9) (9331, Cell Signaling),
GSK3-a/b (sc7291, Santa Cruz), SAPK/JNK (9252, Cell Signaling),
pSAPK/JNK (Thr183/Tyr185) (4671, Cell Signaling), PARP antibody
(9532, Cell Signaling) and p-b-catenin (sc57535, Santa Cruz), b-
catenin (AB6300, Abcam), cyclin D1 (sc246, Santa Cruz), p-ASK1
(S83) (ab47304, Abcam) and p-ASK1 (S966) (ab39402, Abcam)
antibodies were used in 1:100 to 1:500 5% BSA-TBS-T. Actin
(Sigma, A5441), antibodies used for equal loading.
4.2.8. COX activity assay
Huh7 and Mahlavu cells were treated with the compounds or
with DMSO control for 48 h. 30 ng of protein obtained from treated
cells was used per well. For the assessment of the effect of the
molecules on COX activity, Cyclooxygenase (COX) Activity
Assay Kit (Fluorometric) (BioVision, K549-100) was used according
to manufacturer’s protocol. Experiment was conducted in
duplicate.4.3. In silico analysis
4.3.1. QSAR
The 2D molecular structures of the compounds were used to
calculate mono- and bi-dimensional molecular descriptors, as well
as PubChem molecular fragments, by the software PaDEL-Descrip-
tors 2.18.54 Constant descriptors, and descriptors found to be cor-
related (correlation greater than 0.98) were discarded to
minimize redundant information. A random 25% of the compounds
were set aside as the test (‘Prediction’) set; the data split was con-
ducted manually according to the structural similarity of the com-
pounds so that both sets contained all structure classes and the
training set contained the full range of activities.55 Rounds of
Genetic Algorithm refinement of descriptor combinations were
performed in QSARINS56 until the number of descriptors added
to the model exceeded 1/5 of the variables—this allowed for a max-
imum of 5 descriptors. An analysis of R2 versus Q2 revealed that all
5 descriptors improved the model, with Q2 as well as R2 improving
with every addition of descriptor. The QUIK rule57 was applied to
automatically exclude models where the correlation between the
block of the descriptors and the response is lower than or too similar
to the inter-correlation among the descriptors. A relatively stringent
difference cutoff of 0.05 was set as recommended in the QSARINS
manual. The models were also filtered according to the magnitude
of the interval of confidence and significance of the model coeffi-
cients; a stringent confidence interval of 1.5 was set.
This initial first pass revealed that compounds Ibu, Nap, 1 and 2
were structural outliers (as determined by their leverage values
being above the h⁄ value or their predictions being above a residual
threshold of 2.5). These compounds were excluded from both the
training and test sets for the second run; the reduced number of
datapoints meant that only 4 descriptors were included in the
Genetic Algorithm (GA) refinement in order to keep to the 1:5
descriptors:variables limit. This time the R2/Q2 analysis revealed
that only 3 descriptors were required to maximize Q2. In addition,
the confidence interval filter excluded all models with greater than
3 descriptors.
4.3.2. Molecular docking
Water molecules and other hetero atoms were removed and the
program PDB2PQR 1.858 was used to assign position-optimized
hydrogen atoms, utilizing the additional PropKa59 algorithm with
a pH of 7.4 to predict protonation states. The MGLTools 1.5.4 utility
prepare_receptor4.py60 was used to assign Gasteiger charges to
atoms. Hydrogen atoms were assigned to ligand structures using
OpenBabel 2.3.261, utilizing the -p option to predict the protona-
tion states of functional groups at pH 7.4. The MGLTools utility pre-
pare_ligand4.py60 was used to assign Gasteiger charges and
rotatable bonds. A grid box that encompassed the maximum
dimensions of the ligand plus 12 Å in each direction was used.
The starting translation and orientation of the ligand and the tor-
sion angles of all rotatable bonds were set to random. The Autogrid
grid point spacing was set at 0.2 Å. The Autodock parameter file
specified 20 Lamarckian genetic algorithm runs, the number of
energy evaluations as given by the equation T2 * 0.2627
+ T * 0.1551 + 0.2827 (where T is the number of rotatable torsions
in the molecule) and a population size of 300. Autodock62 was used
to automatically fit each compound into the active site of the
receptor protein structure. PyMol 1.7.2.3 was used for visualization
of the results and for figure generation.
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